EpiBiologics
PrivateLast Round
Series B
Jan 8, 2026
Total Funding Raised
$310M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
EpiBiologics operates in Healthcare & Life Sciences and is based in San Mateo, California. Its latest recorded funding round was a Series B round in January 2026.
EpiBiologics is a biotechnology company that develops protein degradation therapeutics aimed at addressing the root causes of disease biology through antibody-based targeted therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpiBiologics Comparables
Compare EpiBiologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pinetree Therapeutics | 83% | |
| Lycia Therapeutics | 81% | |
| Cullgen | 79% |
For institutional investors. Book with your work email.
EpiBiologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 8, 2026 | ||||
| Series B | Jan 8, 2024 | ||||
| Series A Extension | Jul 20, 2023 | ||||
| Series A | Mar 22, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EpiBiologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series B |
| Codon Capital | Series B, Series A, Series A Extension |
| GV | Series B, Series A Extension, Series A |
| Digitalis Ventures | Series B, Series A Extension, Series A |
| Taiho Ventures | Series B, Series A Extension, Series A |
| Mubadala Capital | Series A |
| Mission BioCapital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 65% MoM.
- Jan 8, 2026
Developing an experimental protein-destroying antibody for clinical trials.
For institutional investors. Book with your work email.
EpiBiologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EpiBiologics's valuation, stock price, and market status.
Is EpiBiologics a public or private company?
EpiBiologics is a private company.
What is the current stock price of EpiBiologics?
EpiBiologics is a private company, so its shares have no public market price. Caplight tracks EpiBiologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EpiBiologics worth (valuation)?
Valuation information for EpiBiologics is not publicly available.
Can I buy EpiBiologics stock?
EpiBiologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EpiBiologics's last funding round?
EpiBiologics's most recent funding round was Series B on January 8, 2026.
Who are the main investors in EpiBiologics?
Key investors in EpiBiologics include GV, Mubadala Capital, Mubadala Investment Company, Polaris Partners, Johnson & Johnson Innovation - JJDC, Inc..
Will EpiBiologics IPO soon?
No public IPO plans have been announced for EpiBiologics.
How can I track EpiBiologics secondary market activity?
Caplight tracks bids, offers, and trades in EpiBiologics's shares on secondary markets.